Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.
Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia K, Heales S, Sebire NJ, Zetterberg H, Mills K. Heywood WE, et al. Among authors: magdalinou nk. Mol Neurodegener. 2015 Dec 1;10:64. doi: 10.1186/s13024-015-0059-y. Mol Neurodegener. 2015. PMID: 26627638 Free PMC article.
A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.
Paterson RW, Heywood WE, Heslegrave AJ, Magdalinou NK, Andreasson U, Sirka E, Bliss E, Slattery CF, Toombs J, Svensson J, Johansson P, Fox NC, Zetterberg H, Mills K, Schott JM. Paterson RW, et al. Among authors: magdalinou nk. Transl Psychiatry. 2016 Nov 15;6(11):e952. doi: 10.1038/tp.2016.194. Transl Psychiatry. 2016. PMID: 27845782 Free PMC article.
Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.
Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia KP, Heales S, Sebire NJ, Zetterberg H, Mills K. Heywood WE, et al. Among authors: magdalinou nk. Mol Neurodegener. 2016 Feb 23;11:20. doi: 10.1186/s13024-016-0086-3. Mol Neurodegener. 2016. PMID: 26907468 Free PMC article. No abstract available.
Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW, Slattery CF, Poole T, Nicholas JM, Magdalinou NK, Toombs J, Chapman MD, Lunn MP, Heslegrave AJ, Foiani MS, Weston PSJ, Keshavan A, Rohrer JD, Rossor MN, Warren JD, Mummery CJ, Blennow K, Fox NC, Zetterberg H, Schott JM. Paterson RW, et al. Among authors: magdalinou nk. Alzheimers Res Ther. 2018 Mar 20;10(1):32. doi: 10.1186/s13195-018-0361-3. Alzheimers Res Ther. 2018. PMID: 29558979 Free PMC article.
Increased CSF neurogranin concentration is specific to Alzheimer disease.
Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, Blennow K, Schott JM, Zetterberg H. Wellington H, et al. Neurology. 2016 Mar 1;86(9):829-35. doi: 10.1212/WNL.0000000000002423. Epub 2016 Jan 29. Neurology. 2016. PMID: 26826204 Free PMC article.
CSF neurogranin or tau distinguish typical and atypical Alzheimer disease.
Wellington H, Paterson RW, Suárez-González A, Poole T, Frost C, Sjöbom U, Slattery CF, Magdalinou NK, Lehmann M, Portelius E, Fox NC, Blennow K, Zetterberg H, Schott JM. Wellington H, et al. Among authors: magdalinou nk. Ann Clin Transl Neurol. 2018 Jan 11;5(2):162-171. doi: 10.1002/acn3.518. eCollection 2018 Feb. Ann Clin Transl Neurol. 2018. PMID: 29468177 Free PMC article.
24 results